Relapsing MS Treatment | KESIMPTA® (ofatumumab)

KESIMPTA is now a preferred first-line treatment on Express Scripts®. 93% of all patients with commercial insurance are covered, and 67% have first-line coverage.

*67% of patients with commercial insurance have 1st line coverage.¹

With KESIMPTA, I can fill My TIME MY WAY.

*As evidenced by ARR, MRI (Gd+ T1 and T2 lesions), and 3- and 6-month CDP.²
Real patient who was compensated for time. Individual results may vary.

I’m glad I started RMS treatment with KESIMPTA

Real patient who was compensated for time. Individual results may vary.

Alongside KESIMPTA is here to support your patients

80% of commercial patients receive their first bridge dose in 4 days2

Based on prescription data collected from April to September 2023.

your eligible, commercially insured patients pay as little as a $0† copay

^†Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.

ARR, annualized relapse rate; CDP, confirmed disability progression; DMT, disease-modifying therapy; Gd+, gadolinium-enhancing; MOA, mechanism of action; MRI, magnetic resonance imaging; MS, multiple sclerosis; RMS, relapsing multiple sclerosis; SC, subcutaneous.

IMPORTANT SAFETY INFORMATION

INDICATION